Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06765395 | Explore Association Models Between Environmental Hormones andBreast Cancer | active not recruiting | — | 687 | Pei-Hung LiaoOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05479578 | Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 7 | Rashmi Verma, MDOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06762158 | NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC | active not recruiting | N/A | 50 | RenJi HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04295317 | PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery | active not recruiting | Phase 2 | 65 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT05522231 | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | active not recruiting | Phase 2 / Phase 3 | 265 | HutchmedINDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 3 | 496 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Dec 31, 2024 | clinicaltrials |
| NCT04827953 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer(NUMANTIA) | active not recruiting | Phase 1 / Phase 2 | 28 | Nelum CorpINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT05712902 | Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) | active not recruiting | Phase 2 | 104 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT05869227 | Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 166 | XIANG YANQUNOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06748755 | A Comparative Analysis of Ultrasound's Accuracy in Diagnosing HC Using Histopathology as Gold Standard | active not recruiting | — | 90 | Superior UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06751108 | Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients | active not recruiting | — | 2,000 | Seoul National UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03634540 | A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | active not recruiting | Phase 2 | 118 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03875573 | Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:(Neo-CheckRay) | active not recruiting | Phase 2 | 147 | Jules Bordet InstituteOTHER | 2 | Dec 20, 2024 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06744140 | Role of MRI Breast in Detection of Ductal Carcinoma in Situ | active not recruiting | — | 35 | Superior UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03616886 | Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC(SYNERGY) | active not recruiting | Phase 1 / Phase 2 | 129 | Jules Bordet InstituteOTHER | 2 | Dec 19, 2024 | clinicaltrials |
| NCT02807805 | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 37 | Mamta ParikhOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05879068 | A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | active not recruiting | Phase 2 | 99 | Biotheus Inc.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05121038 | CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab(CENDIFOX) | active not recruiting | Phase 1 / Phase 2 | 50 | Anup KasiOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT02515760 | Tumor-specific T Cells in Lung Cancer | active not recruiting | N/A | 120 | University Hospital HeidelbergOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04794010 | A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer(FINN) | active not recruiting | — | 825 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04811846 | CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood | active not recruiting | N/A | 40 | University Teaching Hospital Hall in TirolOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04843098 | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 108 | Suzhou Junde Biotechnology Co., LtdINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02221778 | SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE | active not recruiting | Phase 2 | 25 | University of Sao PauloOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06247280 | Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation | active not recruiting | — | 2,001 | Yuhan CorporationINDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06717464 | Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer | active not recruiting | Phase 2 | 110 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT01276574 | Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT(Mupet) | active not recruiting | — | 150 | Turku University HospitalOTHER_GOV | 1 | Dec 4, 2024 | clinicaltrials |
| NCT02460887 | The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | active not recruiting | Phase 3 | 236 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03869034 | HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC(HAICPD1-HCC) | active not recruiting | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04956692 | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | active not recruiting | Phase 3 | 531 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Dec 3, 2024 | clinicaltrials |
| NCT04713514 | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC(TEDOVA) | active not recruiting | Phase 2 | 180 | ARCAGY/ GINECO GROUPOTHER | 3 | Dec 2, 2024 | clinicaltrials |
| NCT02167490 | Sentinel Node Vs Observation After Axillary Ultra-souND(SOUND) | active not recruiting | N/A | 1,560 | European Institute of OncologyOTHER | 4 | Nov 25, 2024 | clinicaltrials |
| NCT04923906 | Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations | active not recruiting | Phase 3 | 624 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT04699721 | Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC | active not recruiting | Phase 2 | 60 | Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06700421 | Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis | active not recruiting | Phase 2 | 32 | Wei ZhouOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06239532 | HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma | active not recruiting | Phase 2 | 28 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06699316 | Prognostic Counselling in Palliative Head and Neck Cancer (ProCoPall)(ProCoPall) | active not recruiting | N/A | 160 | Erasmus Medical CenterOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06699524 | Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid | active not recruiting | — | 122 | Shen FengOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT04423731 | Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) | active not recruiting | — | 251 | Oslo University HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02124421 | HOT: HIPEC in Ovarian Cancer as Initial Treatment(CRS/HIPEC) | active not recruiting | Phase 2 | 32 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02387203 | Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin | active not recruiting | Phase 2 | 80 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT04294264 | TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer | active not recruiting | Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05358639 | Combination of Olaparib and Navitoclax in Women with HGSC and TNBC | active not recruiting | Phase 1 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05520619 | Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)(EC-CRT-002) | active not recruiting | Phase 2 | 114 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2025source: clinicaltrials